HemaFlo Therapeutics, has appointed Michael Martino as President, Chief Executive and a member of the Board of Directors.
Most recently Martino was President and Chief Executive of Ambit Biosciences until its acquisition by Daiichi Sankyo.
HemaFlo is a private company founded to develop a platform of Drag Reducing Polymers (DRPs) that have applicability in a number of acute and chronic disease states that are associated with decreased tissue perfusion due to reduced blood flow.
Prior to joining HemaFlo, Martino was President, Chief Executive and a member of the Board of Directors of Ambit Biosciences from 2011 to November 2014.
At Ambit, Martino built and led the team that accelerated the development of the company's lead asset, completed a successful IPO, and closed a merger with Daiichi Sankyo.
Prior to this, he was a co-founder and Chief Executive of Arzeda, a synthetic biology company that he helped spin out of the University of Washington. From 1998 to 2007, he was President, Chief Executive and a member of the Board of Directors of Sonus Pharmaceuticals, a publicly traded oncology company.
Martino began his career with Mallinckrodt Pharmaceuticals in 1983 where, over 15 years, he held positions in planning, business development, marketing and general management, including as Vice President and General Manager of the firm's global nuclear medicine business.
